skip to main content
Resultados 1 2 3 next page
Refinado por: Nome da Publicação: Hematological Oncology remover tipo de recurso: Artigos remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
CHARACTERISTICS OF PATIENTS ACHIEVING COMPLETE OR PARTIAL RESPONSE (CR/PR) WITH TAZEMETOSTAT (TAZ) IN WILD‐TYPE RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
Material Type:
Artigo
Adicionar ao Meu Espaço

CHARACTERISTICS OF PATIENTS ACHIEVING COMPLETE OR PARTIAL RESPONSE (CR/PR) WITH TAZEMETOSTAT (TAZ) IN WILD‐TYPE RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

Batlevi, C. L. ; Salles, G. ; Tilly, H. ; Chaidos, A. ; McKay, P. ; Phillips, T. ; Assouline, S. ; Campbell, P. ; Ribrag, V. ; Damaj, G. Laurent ; Dickinson, M. ; Jurczak, W. ; Kaźmierczak, M. ; Opat, S. ; Radford, J. R. ; Schmitt, A. ; Rajarethinam, A. ; Shang, G. ; Morschhauser, F.

Hematological oncology, 2021-06, Vol.39 (S2) [Periódico revisado por pares]

Chichester: Wiley Subscription Services, Inc

Texto completo disponível

2
Analysis of Real‐World Treatment Patterns and Outcomes Among Patients With Relapsed/Refractory Follicular Lymphoma Including POD24 Patients
Material Type:
Artigo
Adicionar ao Meu Espaço

Analysis of Real‐World Treatment Patterns and Outcomes Among Patients With Relapsed/Refractory Follicular Lymphoma Including POD24 Patients

Sehn, L. H. ; Wang, A. ; Yu, J. ; Kamalakar, R. ; Sail, K. ; Sinai, W. ; Arnette, D. ; Yang, S. ; Mutebi, A. ; Navarro, F. R. ; Salles, G.

Hematological oncology, 2023-06, Vol.41 (S2), p.373-375 [Periódico revisado por pares]

Texto completo disponível

3
CAR‐HEMATOTOX: A DISCRIMINATIVE MODEL FOR CAR T‐CELL RELATED HEMATOTOXICITY IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA
Material Type:
Artigo
Adicionar ao Meu Espaço

CAR‐HEMATOTOX: A DISCRIMINATIVE MODEL FOR CAR T‐CELL RELATED HEMATOTOXICITY IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA

Rejeski, K. ; Perez, A. ; Sesques, P. ; Berger, C. ; Jentzsch, L. ; Mougiakakos, D. ; Frölich, L. ; Ackermann, J. ; Bücklein, V. ; Blumenberg, V. ; Schmidt, C. ; Jallades, L. ; Fehse, B. ; Faul, C. ; Karschnia, P. ; Weigert, O. ; Dreyling, M. ; Hoster, E. ; Locke, F. ; von Bergwelt‐Baildon, M. ; Mackensen, A. ; Bethge, W. ; Ayuk, F. ; Bachy, E. ; Salles, G. ; Jain, M. ; Subklewe, M.

Hematological oncology, 2021-06, Vol.39 (S2) [Periódico revisado por pares]

Chichester: Wiley Subscription Services, Inc

Texto completo disponível

4
CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE POLARIX STUDY
Material Type:
Artigo
Adicionar ao Meu Espaço

CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE POLARIX STUDY

Herrera, A. F. ; Tracy, S. ; Sehn, L. H. ; Jardin, F. ; Lenz, G. ; Trněný, M. ; Salles, G. ; Flowers, C. R. ; Tilly, H. ; Sharman, J. P. ; Friedberg, J. W. ; Balasubramanian, S. ; Raghavan, V. ; Hirata, J. ; Lee, C. ; Jiang, Y. ; Morschhauser, F.

Hematological oncology, 2023-06, Vol.41 (S2), p.175-177 [Periódico revisado por pares]

Texto completo disponível

5
Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND study
Material Type:
Artigo
Adicionar ao Meu Espaço

Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND study

Duell, J. ; Abrisqueta, P. ; Andre, M. ; Augustin, M. ; Gaidano, G. ; Barca, E. G. ; Jurczak, W. ; Kalakonda, N. ; Liberati, A. M. ; Maddocks, K. J. ; Menne, T. ; Nagy, Z. ; Tournilhac, O. ; Bakuli, A. ; Amin, A. ; Gurbanov, K. ; Salles, G.

Hematological oncology, 2023-06, Vol.41 (S2), p.437-439 [Periódico revisado por pares]

Texto completo disponível

6
Five‐year subgroup analysis of tafasitamab + lenalidomide from the Phase II L‐MIND study in patients with relapsed or refractory diffuse large B‐cell lymphoma
Material Type:
Artigo
Adicionar ao Meu Espaço

Five‐year subgroup analysis of tafasitamab + lenalidomide from the Phase II L‐MIND study in patients with relapsed or refractory diffuse large B‐cell lymphoma

Duell, J. ; Abrisqueta, P. ; Dreyling, M. ; Gaidano, G. ; Barca, E. G. ; Jurczak, W. ; Maddocks, K. J. ; Menne, T. ; Nagy, Z. ; Tournilhac, O. ; Bakuli, A. ; Amin, A. ; Gurbanov, K. ; Salles, G.

Hematological oncology, 2023-06, Vol.41 (S2), p.439-441 [Periódico revisado por pares]

Texto completo disponível

7
TREATMENT‐DEPENDENCE OF HIGH‐RISK GENE EXPRESSION SIGNATURES IN DE NOVO FOLLICULAR LYMPHOMA
Material Type:
Artigo
Adicionar ao Meu Espaço

TREATMENT‐DEPENDENCE OF HIGH‐RISK GENE EXPRESSION SIGNATURES IN DE NOVO FOLLICULAR LYMPHOMA

Bolen, C.R. ; Hiddemann, W. ; Marcus, R. ; Herold, M. ; Huet, S. ; Salles, G. ; Mattiello, F. ; Nielsen, T. ; Mir, F. ; Venstrom, J.M. ; Oestergaard, M.Z.

Hematological oncology, 2019-06, Vol.37 (S2), p.193-194 [Periódico revisado por pares]

Chichester: Wiley Subscription Services, Inc

Texto completo disponível

8
INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Material Type:
Artigo
Adicionar ao Meu Espaço

INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Morschhauser, F. ; Tilly, H. ; Chaidos, A. ; Phillips, T. ; Ribrag, V. ; Campbell, P. ; Ghandi Laurent, D. ; Jurczak, W. ; McKay, P. ; Opat, S. ; Radford, J. ; Rajarethinam, A. ; Yang, J. ; Howell, H. ; Newberry, K.J. ; Adib, D. ; Salles, G.

Hematological oncology, 2019-06, Vol.37 (S2), p.154-156 [Periódico revisado por pares]

Chichester: Wiley Subscription Services, Inc

Texto completo disponível

9
PRIMARY ANALYSIS RESULTS OF THE SINGLE‐ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (L‐MIND)
Material Type:
Artigo
Adicionar ao Meu Espaço

PRIMARY ANALYSIS RESULTS OF THE SINGLE‐ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (L‐MIND)

Salles, G. ; Duell, J. ; González Barca, E. ; Jurczak, W. ; Liberati, A.M. ; Nagy, Z. ; Obr, A. ; Gaidano, G. ; Andre, M. ; Kalakonda, N. ; Dreyling, M. ; Zinzani, P.L. ; Dirnberger‐Hertweck, M. ; Weirather, J. ; Ambarkhane, S. ; Maddocks, K.

Hematological oncology, 2019-06, Vol.37 (S2), p.173-174 [Periódico revisado por pares]

Chichester: Wiley Subscription Services, Inc

Texto completo disponível

10
POLARIX: A PHASE 3 STUDY OF POLATUZUMAB VEDOTIN (POLA) PLUS R‐CHP VERSUS R‐CHOP IN PATIENTS (PTS) WITH UNTREATED DLBCL
Material Type:
Artigo
Adicionar ao Meu Espaço

POLARIX: A PHASE 3 STUDY OF POLATUZUMAB VEDOTIN (POLA) PLUS R‐CHP VERSUS R‐CHOP IN PATIENTS (PTS) WITH UNTREATED DLBCL

Tilly, H. ; Flowers, C. ; Friedberg, J.W. ; Herbaux, C. ; Morschhauser, F. ; Sehn, L.H. ; Sharman, J. ; Trněný, M. ; Lee, C. ; Salles, G.

Hematological oncology, 2019-06, Vol.37 (S2), p.68-70 [Periódico revisado por pares]

Chichester: Wiley Subscription Services, Inc

Texto completo disponível

Resultados 1 2 3 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Data de Publicação 

De até

Buscando em bases de dados remotas. Favor aguardar.